2017 U.S.-Booked Air Volume: $57 million
Primary Global TMC: BCD
Biopharmaceutical company Shire launched 50 products in 25
countries in 2017, increased its pro forma product sales growth by 8 percent to
$14.4 billion, an increase of over $1 billion. It invested $1.8 billion in
R&D last year and in 2018 plans targeted investments in its manufacturing
infrastructure, product launches and clinical pipeline. In 2017, it cut its
carbon emissions, including those from business travel. As of the end of the
year, it employed 23,044 in over 60 countries.